- The P-III study involve assessing Nucala (300mg, q4w, SC) vs PBO in 108 adolescent and adult patients with severe HES for 32wks.
- The P-III study results: met its 1EPs i.e, reduction in flares with 50% fewer patients experiencing HES flare (56% vs 28%). 2EPs: 66% lower risk of first HES flare; 66% reduction in the annualized rate of HES flares; improvement in fatigue score; safety results were consistent with the known profile of Nucala
- Nucala is mAb targeting IL-5, first treatment demonstrating a reduction in flares in HES and has received the FDA & EMA’s ODD to treat HES with its anticipated regulatory submission in 2020
Click here to read full press release/ article | Ref: GSK | Image: Nypost